A Companion Diagnostics (CDx) assay is a test designed to identify patients who are most likely to benefit from a specific targeted therapy by measuring relevant biomarkers.

Current CDx tests are often qualitative or semi-quantitative, leading to inaccurate patient selection. Nearly 30% of patients treated with targeted therapies may experience worse outcomes, including reduced survival due to misclassification of many patients as eligible for targeted treatments, resulting in no benefit, increased toxicity, and up to $70,000 per patient per year wasted on ineffective therapies.

How QDB Technology Improves CDx

Our fully quantitative QDB system transforms CDx by providing precise, reproducible biomarker measurements. This enables accurate identification of true responders to targeted therapies, reduces misclassification, and ensures that only patients who will genuinely benefit are selected for treatment. With QDB, clinicians can make confident, data-driven decisions, improving patient outcomes and reducing unnecessary costs.

We are the only company capable of finding this cut-off point and identifying true responders—and uniquely able to determine when a targeted therapy may actually harm rather than help. By integrating QDB technology, our companion diagnostic (CDx) services deliver quantitative, consistent, and clinically validated biomarker measurements—empowering confident, personalized treatment decisions and maximizing the effectiveness of targeted therapies.